| Literature DB >> 33224366 |
Shahid Habib1, Sandeep Yarlagadda2, Teresia A Carreon1, Lindsey M Schader1, Chiu-Hsieh Hsu3.
Abstract
BACKGROUND: Infection in acute-on-chronic liver failure (ACLF) patients is known to cause higher mortality. The current approach is to culture all patient samples. There are no published data evaluating fungal infections in acutely decompensated patients. In this study, we aim to identify clinical factors predictive of infections within ACLF patients and assess workup compliance within 24 h of hospital admission.Entities:
Keywords: Acute-on-chronic liver failure; Bacterial infection; Fungal infection; Liver disease
Year: 2020 PMID: 33224366 PMCID: PMC7665857 DOI: 10.14740/gr1255
Source DB: PubMed Journal: Gastroenterology Res ISSN: 1918-2805
Identification of Factors Associated With Any Infection (N = 457)
| Variable | Infection frequency (%)/mean ± SD | OR (95% CI) | C-statistics | P value |
|---|---|---|---|---|
| SIRS criteria, Y/N (n = 455) | 159 (84.13)/116 (43.61) | 6.85 (4.33, 10.85) | 0.71 | < 0.0001 |
| Sex, male/female | 164 (55.78)/113 (69.33) | 0.56 (0.37, 0.84) | 0.57 | < 0.01 |
| DM, Y/N (n = 455) | 103 (68.67)/173 (56.72) | 1.67 (1.11, 2.53) | 0.56 | 0.01 |
| CKD, Y/N (n = 456) | 36 (66.67)/240 (59.70) | 1.35 (0.74, 2.46) | 0.52 | 0.33 |
| HD, Y/N | 21 (87.50)/256 (59.12) | 4.84 (1.42, 16.45) | 0.53 | 0.01 |
| Chemotherapy, Y/N (n = 449) | 2 (28.57)/269 (60.86) | 0.26 (0.05, 1.34) | 0.51 | 0.11 |
| Immunotherapy, Y/N (n = 454) | 20 (55.56)/256 (61.24) | 0.79 (0.40, 1.57) | 0.51 | 0.50 |
| History of | 13 (76.47)/264 (60.00) | 2.17 (0.70, 6.75) | 0.51 | 0.18 |
| History of cocci, Y/N | 7 (50.00)/270 (60.95) | 0.64 (0.22, 1.86) | 0.51 | 0.41 |
| TIPS, Y/N | 28 (65.12)/249 (60.14) | 1.24 (0.64, 2.39) | 0.51 | 0.53 |
| Ever smoker, Y/N (n = 453) | 137 (58.05)/137 (63.13) | 0.81 (0.55, 1.18) | 0.53 | 0.27 |
| Ever drinker, Y/N (n = 442) | 164 (56.55)/103 (67.76) | 0.62 (0.41, 0.94) | 0.55 | 0.02 |
| Antibiotic, Y/N (n = 441) | 38 (76.00)/229 (58.57) | 2.24 (1.14, 4.42) | 0.54 | 0.02 |
| Supplements, Y/N (n = 456) | 36 (61.02)/240 (60.45) | 1.02 (0.59, 1.79) | 0.50 | 0.93 |
| Lactate (n = 314) | 3.29 ± 2.77 | 1.19 (1.05, 1.34) | 0.58 | < 0.01 |
| Platelet | 117.28 ± 78.21 | 0.999 (0.997, 1.002) | 0.53 | 0.58 |
| Fib-4 | 12.09 ± 26.13 | 1.003 (0.995, 1.011) | 0.51 | 0.48 |
| APRI | 5.11 ± 17.57 | 1.01 (0.99, 1.02) | 0.48 | 0.38 |
| CTP | 11.48 ± 1.46 | 1.10 (0.96, 1.25) | 0.54 | 0.16 |
| MELD (n = 428) | 18.73 ± 8.52 | 1.04 (1.02, 1.07) | 0.60 | < 0.01 |
| Age (n = 456) | 55.50 ± 10.87 | 1.03 (1.02, 1.05) | 0.60 | < 0.001 |
| WBC (n = 456) | 9.08 ± 6.03 | 1.08 (1.04, 1.12) | 0.58 | < 0.0001 |
| Hb | 11.16 ± 2.78 | 0.99 (0.92, 1.06) | 0.51 | 0.74 |
| PT (n = 433) | 21.42 ± 17.95 | 1.00 (0.99, 1.01) | 0.56 | 0.67 |
| INR (n= 433) | 1.69 ± 0.96 | 1.25 (0.98, 1.61) | 0.57 | 0.08 |
| PTT (n = 231) | 38.57 ± 16.80 | 1.03 (1.00, 1.06) | 0.58 | < 0.05 |
| TB (n = 453) | 5.00 ± 6.32 | 0.99 (0.97, 1.02) | 0.49 | 0.69 |
| DB (n = 106) | 5.70 ± 5.51 | 0.99 (0.92, 1.06) | 0.45 | 0.73 |
| ALB (n = 402) | 3.43 ± 12.04 | 1.01 (0.98, 1.05) | 0.42 | 0.45 |
| ALP (n = 455) | 163.77 ± 128.99 | 0.999 (0.997, 1.000) | 0.51 | 0.18 |
| AST | 115.86 ± 248.31 | 1.00 (0.999, 1.001) | 0.47 | 0.54 |
| ALT | 64.95 ± 155.36 | 1.00 (0.999, 1.001) | 0.46 | 0.77 |
| Cr (n = 454) | 1.54 ± 1.88 | 1.19 (1.03, 1.38) | 0.60 | 0.02 |
Y/N: yes/no; SD: standard deviation; C-statistic: concordance statistic; OR: odds ratio; CI: confidence interval; SIRS: systemic inflammatory response syndrome; DM: diabetes mellitus; CKD: chronic kidney diseases; HD: hemodialysis; TIPS: transjugular intrahepatic portosystemic shunt; Fib-4: fibrosure-4; APRI: AST to platelet ration index; CTP: Child-Turcotte-Pugh; MELD: model for end-stage liver disease; WBC: white blood cell count; Hb: hemoglobin; PT: prothrombin; INR: international normalized ratio; PTT: prothrombin time; TB: total bilirubin; DB: direct bilirubin; ALB: albumin; ALP: alkaline phosphatase test; AST: aspartate aminotransferase; ALT: alanine transaminase; Cr: creatinine.
Identification of Factors Associated With Bacterial Infection (N = 457)
| Variable | Infection frequency (%)/mean ± SD | OR (95% CI) | C-statistics | P value |
|---|---|---|---|---|
| SIRS criteria, Y/N (n = 455) | 114 (60.32)/92 (34.59) | 2.88 (1.96, 4.23) | 0.63 | < 0.0001 |
| Sex, male/female | 120 (40.82)/86 (52.76) | 0.62 (0.42, 0.91) | 0.56 | 0.01 |
| DM, Y/N (n = 455) | 70 (46.67)/135 (44.26) | 1.10 (0.74, 1.63) | 0.51 | 0.63 |
| CKD, Y/N (n = 456) | 28 (51.85)/177 (44.03) | 1.37 (0.78, 2.42) | 0.52 | 0.28 |
| HD, Y/N | 15 (62.50)/191 (44.11) | 2.11 (0.90, 4.93) | 0.52 | 0.08 |
| Chemotherapy, Y/N (n = 449) | 1 (14.29)/200 (45.25) | 0.20 (0.02, 1.69) | 0.51 | 0.14 |
| Immunotherapy, Y/N (n = 454) | 12 (33.33)/194 (46.41) | 0.58 (0.28, 1.19) | 0.52 | 0.13 |
| History of | 7 (41.18)/199 (45.23) | 0.85 (0.32, 2.27) | 0.50 | 0.74 |
| History of cocci, Y/N | 5 (35.71)/201 (45.37) | 0.67 (0.22, 2.03) | 0.51 | 0.48 |
| TIPS, Y/N | 25 (58.14)/181 (43.72) | 1.79 (0.95, 3.38) | 0.53 | 0.07 |
| Ever smoker, Y/N (n = 453) | 94 (39.83)/109 (50.23) | 0.66 (0.45, 0.95) | 0.55 | 0.03 |
| Ever drinker, Y/N (n = 442) | 121 (41.72)/77 (50.66) | 0.70 (0.47, 1.04) | 0.54 | 0.07 |
| Antibiotic, Y/N (n = 441) | 28 (56.00)/172 (43.99) | 1.62 (0.90, 2.93) | 0.52 | 0.11 |
| Supplements, Y/N (n = 456) | 27 (45.76)/179 (45.09) | 1.03 (0.59, 1.78) | 0.50 | 0.92 |
| Lactate (n = 314) | 3.29 ± 2.77 | 1.11 (1.01, 1.21) | 0.58 | 0.02 |
| Platelet | 117.28 ± 78.21 | 1.001 (0.999, 1.004) | 0.52 | 0.23 |
| Fib-4 | 12.09 ± 26.13 | 1.003 (0.996, 1.010) | 0.47 | 0.40 |
| APRI | 5.11 ± 17.57 | 1.01 (0.99, 1.02) | 0.45 | 0.28 |
| CTP | 11.48 ± 1.46 | 1.16 (1.02, 1.32) | 0.57 | 0.02 |
| MELD (n = 428) | 18.73 ± 8.52 | 1.02 (1.00, 1.05) | 0.56 | 0.05 |
| Age (n = 456) | 55.50 ± 10.87 | 1.03 (1.01, 1.05) | 0.59 | < 0.01 |
| WBC (n = 456) | 9.08 ± 6.03 | 1.06 (1.03, 1.10) | 0.58 | < 0.001 |
| Hb | 11.16 ± 2.78 | 0.98 (0.92, 1.05) | 0.51 | 0.58 |
| PT (n = 433) | 21.42 ± 17.95 | 1.01 (0.99, 1.02) | 0.55 | 0.35 |
| INR (n = 433) | 1.69 ± 0.96 | 1.20 (0.97, 1.49) | 0.55 | 0.09 |
| PTT (n = 231) | 38.57 ± 16.80 | 1.01 (0.99, 1.03) | 0.57 | 0.28 |
| TB (n = 453) | 5.00 ± 6.32 | 0.98 (0.95, 1.01) | 0.52 | 0.27 |
| DB (n = 106) | 5.70 ± 5.51 | 1.00 (0.93, 1.07) | 0.51 | 0.95 |
| ALB (n = 402) | 3.43 ± 12.04 | 1.00 (0.98, 1.01) | 0.53 | 0.73 |
| ALP (n = 455) | 163.77 ± 128.99 | 0.999 (0.997, 1.000) | 0.54 | 0.13 |
| AST | 115.86 ± 248.31 | 1.000 (0.999, 1.001) | 0.47 | 0.84 |
| ALT | 64.95 ± 155.36 | 1.000 (0.998, 1.001) | 0.57 | 0.62 |
| Cr (n = 454) | 1.54 ± 1.88 | 1.10 (0.98, 1.22) | 0.59 | 0.09 |
Y/N: yes/no; SD: standard deviation; C-statistic: concordance statistic; OR: odds ratio; CI: confidence interval; SIRS: systemic inflammatory response syndrome; DM: diabetes mellitus; CKD: chronic kidney diseases; HD: hemodialysis; TIPS: transjugular intrahepatic portosystemic shunt; Fib-4: fibrosure-4; APRI: AST to platelet ration index; CTP: Child-Turcotte-Pugh; MELD: model for end-stage liver disease; WBC: white blood cell count; Hb: hemoglobin; PT: prothrombin; INR: international normalized ratio; PTT: prothrombin time; TB: total bilirubin; DB: direct bilirubin; ALB: albumin; ALP: alkaline phosphatase test; AST: aspartate aminotransferase; ALT: alanine transaminase; Cr: creatinine.
Identification of Factors Associated With Fungal Infections (N = 457)
| Variable | Infection frequency (%)/mean ± SD | OR (95% CI) | C-statistics | P value |
|---|---|---|---|---|
| SIRS criteria, Y/N (n = 455) | 12 (6.35)/13 (4.89) | 1.32 (0.59, 2.96) | 0.53 | 0.50 |
| Sex, male/female | 13 (4.42)/12 (7.36) | 0.58 (0.26, 1.31) | 0.57 | 0.19 |
| DM, Y/N (n = 455) | 11 (7.33)/14 (4.59) | 1.65 (0.73, 3.72) | 0.56 | 0.23 |
| CKD, Y/N (n = 456) | 4 (7.41)/21 (5.22) | 1.45 (0.48, 4.40) | 0.52 | 0.51 |
| HD, Y/N | 1 (4.17)/24 (5.54) | 0.74 (0.10, 5.72) | 0.51 | 0.77 |
| Chemotherapy, Y/N (n = 449) | 1 (14.29)/24 (5.43) | 2.90 (0.34, 25.09) | 0.51 | 0.33 |
| Immunotherapy, Y/N (n = 454) | 3 (8.33)/22 (5.26) | 1.64 (0.47, 5.75) | 0.52 | 0.44 |
| History of | 0 (0)/25 (5.68) | NA | 0.52 | 0.98 |
| History of cocci, Y/N | 0 (0)/25 (5.64) | NA | 0.52 | 0.98 |
| TIPS, Y/N | 1 (2.33)/24 (5.80) | 0.39 (0.05, 2.93) | 0.53 | 0.36 |
| Ever smoker, Y/N (n = 453) | 13 (5.51)/12 (5.53) | 1.00 (0.44, 2.23) | 0.50 | 0.99 |
| Ever drinker, Y/N (n = 442) | 15 (5.17)/9 (5.92) | 0.87 (0.37, 2.03) | 0.52 | 0.74 |
| Antibiotic, Y/N (n = 441) | 5 (10.00)/20 (5.12) | 2.06 (0.74, 5.76) | 0.55 | 0.17 |
| Supplements, Y/N (n = 456) | 2 (3.39)/23 (5.79) | 0.57 (0.13, 2.49) | 0.53 | 0.45 |
| Lactate (n = 314) | 3.29 ± 2.77 | 1.10 (0.98, 1.25) | 0.62 | 0.11 |
| Platelet | 117.28 ± 78.21 | 0.996 (0.990, 1.002) | 0.55 | 0.21 |
| Fib-4 | 12.09 ± 26.13 | 1.00 (0.99, 1.02) | 0.57 | 0.76 |
| APRI | 5.11 ± 17.57 | 0.99 (0.95, 1.03) | 0.45 | 0.67 |
| CTP | 11.48 ± 1.46 | 1.20 (0.91, 1.60) | 0.55 | 0.20 |
| MELD (n = 428) | 18.73 ± 8.52 | 1.06 (1.01, 1.10) | 0.69 | 0.01 |
| Age (n = 456) | 55.50 ± 10.87 | 1.01 (0.98, 1.05) | 0.53 | 0.53 |
| WBC (n = 456) | 9.08 ± 6.03 | 0.96 (0.89, 1.04) | 0.51 | 0.35 |
| Hb | 11.16 ± 2.78 | 0.84 (0.72, 0.97) | 0.64 | 0.02 |
| PT (n = 433) | 21.42 ± 17.95 | 1.013 (1.001, 1.026) | 0.70 | 0.03 |
| INR (n = 433) | 1.69 ± 0.96 | 1.34 (1.03, 1.74) | 0.71 | 0.03 |
| PTT (n = 231) | 38.57 ± 16.80 | 1.015 (0.996, 1.034) | 0.73 | 0.13 |
| TB (n = 453) | 5.00 ± 6.32 | 1.052 (1.004, 1.102) | 0.63 | 0.03 |
| DB (n = 106) | 5.70 ± 5.51 | 0.91 (0.76, 1.10) | 0.52 | 0.35 |
| ALB (n = 402) | 3.43 ± 12.04 | 1.013 (0.996, 1.031) | 0.41 | 0.13 |
| ALP (n = 455) | 163.77 ± 128.99 | 0.999 (0.995, 1.003) | 0.53 | 0.59 |
| AST | 115.86 ± 248.31 | 0.996 (0.990, 1.003) | 0.52 | 0.27 |
| ALT | 64.95 ± 155.36 | 0.99 (0.98, 1.01) | 0.56 | 0.18 |
| Cr (n = 454) | 1.54 ± 1.88 | 1.01 (0.82, 1.25) | 0.51 | 0.89 |
Y/N: yes/no; SD: standard deviation; C-statistic: concordance statistic; OR: odds ratio; CI: confidence interval; SIRS: systemic inflammatory response syndrome; DM: diabetes mellitus; CKD: chronic kidney diseases; HD: hemodialysis; TIPS: transjugular intrahepatic portosystemic shunt; Fib-4: fibrosure-4; APRI: AST to platelet ration index; CTP: Child-Turcotte-Pugh; MELD: model for end-stage liver disease; WBC: white blood cell count; Hb: hemoglobin; PT: prothrombin; INR: international normalized ratio; PTT: prothrombin time; TB: total bilirubin; DB: direct bilirubin; ALB: albumin; ALP: alkaline phosphatase test; AST: aspartate aminotransferase; ALT: alanine transaminase; Cr: creatinine.
Cutoffs for Fungal Infection (N = 457)
| Variable | Best cutoffa | Sensitivityb | Specificityb | Youdenc |
|---|---|---|---|---|
| MELD | 19.33 | 81.8% | 58.6% | 40.4% |
| Total bilirubin | 4.20 | 64.0% | 67.8% | 31.8% |
| International normalized ratio | 1.50 | 79.2% | 54.8% | 33.9% |
| Hemoglobin | 11.30 | 76.0% | 49.8% | 25.8% |
aThe value maximizes Youden statistic. bROC analysis was performed to derive sensitivity and specificity based on a logistic regression model with the continuous variable of interest (e.g., MELD) as the only covariate. cYouden = sensitivity + specificity - 1. MELD: model for end-stage liver disease; ROC: receiver operating characteristic.
Figure 1Logistic regression analysis demonstrates the association between the proportion of basic infectious workup tests completed and infection status. Analysis is based on the area under the ROC curve. ROC: receiver operating characteristic.